Salvage Treatment for HIV- Part II

Mega-HAART or MDRT

The second phase of salvage treatment for HIV is Mega-HAART or MDRT.

HAART (Highly Active Anti-Retroviral Therapy)

Combination treatment for HIV generally comprises of a protease inhibitor. Merger of medications have been observed to vastly suppress HIV and this approach aids in delaying or avoiding the growth of therapy resistant viral mutant forms.

Mega-HAART

These are drug mergers that comprise of five or more HIV combatant drugs; generally 2-3 protease inhibitors.

MDRT

MDRT or multiple drug rescue therapy involved the use of far greater amounts of antiretroviral that could be tolerated by the patient. Several researches have employed up to nine drugs during MDRT sessions. Majority of the individuals that conduct such researches have fallen short of medication options with multiple resistances to all medication categories being observed and CD4 count in such cases being as less as twenty cells per millimeter cube. There have been widespread concerns regarding safety and drug tolerance levels in case of MDRT. When belligerent MDRT strategies were employed on HIV strains showing high resistance, the outcomes have exhibited survival advantages analogous to those observed in treatment for HIV among individuals employing normal HAART.

NOVEL DRUGS (EXPANDED-ACCESS)

Expanded access is a generalized terminology used for techniques involving distribution of investigational medications to patients that are incapable of participating in on-going clinical studies and are left without any therapy choices. Particular forms of expanded-access methods involve Investigational New Drug (IND), parallel track and compassionate usage.

For people that are continually experiencing increasing viral load along with MDRT or Mega-HAART, the deployment of new-fangled medications could offer them the best possible assistance. Several drugs are still under-development and hold potential, however producing optimal outcomes in case they are backed by other effectual medications in a combo regime.

Novel group of medications that would be vastly beneficial are:

• Entry or fusion inhibitors – A medication intended on inhibiting binding and access of HIV into CD4 cells.
• Assembly, Budding inhibitor Drugs – These medications restrain the concluding phase of virus’s life-cycle when formation of an undeveloped viral element occurs and then pinching it off from the cell, acquiring a covering and HIV proteins from the cell’s membranes.
• Metabolism Modulator
• Curative Vaccinations
• Cytokines – These are dissolvable, hormone-similar matter created and emitted from lymphocyte and macrophage types that function like inter-cellular envoys.

Novel combos of T20 fusion inhibitors and NNRTI show potential but a downside to T20 use is the administration of shots two times daily.

MODEST STRATEGY

Salvage treatment for HIV also involves continuing with the present combo, despite an increasing viral load. This choice has duo risk aspects – side-effects persisting or deteriorating and HIV continually evolving possibly into a far greater resistant type.

Despite combination therapy in certain cases failing to do anything significant against HIV in a patient’s system, but the drug-resistant alterations which they have produced in that HIV strain could lower viral fitness which gives lesser viral load and at times lesser harm to immune system in comparison to what would have happened when no therapy was given.

Irrespective of the process, the worth of an unsuccessful medication regime would wane when there is surge in HIV mutation. It is considered sensible to continue with a poor combo as in case the combo is bearable and easy-to-take or in case the virus stays prone to a minimal of a single medication which is kept aside while the wait continues for novel and greater-potency medications.

Read more at: Salvage Treatment for HIV- Part I

Popularity: 1% [?]